Evidence map›Paper›PMID 36129153›Full record

ArticleOncology reports2022

Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib‑based treatment response and survival via the microRNA‑608‑mediated Wnt/β‑catenin pathway.

Lu Li, Jin Liu, Juan Du, Hua Jiang, Haiyan He, Jing Lu, Wanting Qiang, Nan Hou, Pei Guo, Yan Zhuang and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Recent Progress of CircRNAs in Hematological Malignancies.International journal of medical sciences · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Lu Li *Department of Hematology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200081, P.R. China.
Jin Liu *Department of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Juan DuDepartment of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Hua JiangDepartment of Hematology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200081, P.R. China.
Haiyan HeDepartment of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Jing LuDepartment of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Wanting QiangDepartment of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Nan HouDepartment of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Pei GuoDepartment of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Yan ZhuangDepartment of Hematology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.
Weijun FuDepartment of Hematology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200081, P.R. China.
Second Military Medical University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNA (circRNA/circ) profiles have been suggested to be involved in the prognosis of several types of solid tumors and hematological malignancies, including multiple myeloma (MM). Therefore, the aim of the present study was to comprehensively explore the involvement of circRNA profiles in MM prognosis. A total of 60 patients with MM that underwent bortezomib‑based induction therapy were enrolled. Next, eight patients with complete response (CR) and eight with no response (NR) were randomly selected to detect their circRNA profiles in bone marrow plasma cells (BMPCs) by microarray. Next, 10 candidate circRNAs were verified via reverse transcription‑quantitative PCR (RT‑qPCR) in the BMPCs of 60 patients with MM. Finally, the molecular mechanism of circ_0026652 knockdown underlying the regulation of chemosensitivity to bortezomib was assessed. Microarray showed that 79 circRNAs were upregulated and 167 were downregulated in CR compared with NR cases, which were found to be enriched in carcinogenic and chemoresistance‑related pathways (Wnt, mTOR and MAPK pathways). RT‑qPCR showed that 8/10 circRNAs (circ_0026652, circ_0068708, circ_0088128, circ_0001566, circ_0031113, circ_0083587, circ_0005552 and circ_0007171) were associated with treatment response [CR or objective response rate (ORR)] and 5/10 circRNAs (circ_0026652, circ_0068708, circ_0001566, circ_0031113 and circ_0005552) were associated with progression‑free survival (PFS) or overall survival (OS). Of note, circ_0026652 was a key prognostic marker simultaneously associated with CR, ORR, PFS and OS. Cellular experiments showed that circ_0026652 knockdown enhanced chemosensitivity to bortezomib through the microRNA (miR)‑608‑mediated Wnt/β‑catenin pathway in U266 and RPIM‑8226 cells. In conclusion, dysregulated circRNA profiles were closely associated with MM prognosis, with circ_0026652 being linked to bortezomib‑based treatment response and survival through the miR‑608‑mediated Wnt/β‑catenin pathway.

Indexed as

MicroRNAsMultiple Myelomabeta CateninBortezomibHumansPrognosisRNA, CircularTOR Serine-Threonine Kinasesbeta CateninBortezomibMicroRNAsMIRN608 microRNA, humanRNA, CircularTOR Serine-Threonine Kinaseschemosensitivity to bortezomibcircular RNA 0026652circular RNA profilesmultiple myelomaprognosis

Identifiers

PMID36129153
PMCPMC9535628
OpenAlexW4296058034

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.